Clinical Trials Logo

Accurate Medication clinical trials

View clinical trials related to Accurate Medication.

Filter by:
  • None
  • Page 1

NCT ID: NCT03261908 Not yet recruiting - Pharmacogenomics Clinical Trials

A Pharmacogenomics Study of Simvastatin-Induced Adverse Drug Reaction

Start date: August 2017
Phase: N/A
Study type: Observational

Adverse reactions of simvastatin are mostly slight and transient, however, the incidence of simvastatin-induced hepatic impairment and myopathy are obviously higher in Chinese population than other racial groups. There is still lack of research data in Chinese. In this study, we will investigate whether there are specific genotypes which may predict the incidence of simvastatin-induced hepatic impairment and myopathy in Chinese so as to provide a basis for developing guidelines on precise medication in simvastatin therapy apply to Chinese population.

NCT ID: NCT03259399 Recruiting - Pharmacogenomics Clinical Trials

A Pharmacogenomics Study of Enalapril-Induced Adverse Drug Reaction

Start date: August 16, 2017
Phase: N/A
Study type: Observational

Dry cough is the most common adverse reaction of angiotensin converting enzyme, including enalapril, in Chinese population. Clinical observations suggest that the incidence of ACEI-induced dry cough is different between Chinese and other racial groups, however, there is still lack of research data in Chinese. In this study, we will investigate whether there are specific genotypes which may predict the incidence of enalapril-induced dry cough in Chinese so as to provide a basis for developing guidelines on precise medication in enalapril therapy apply to Chinese population.

NCT ID: NCT03161496 Recruiting - Pharmacokinetics Clinical Trials

A Research in Pharmacogenomics and Accurate Medication of Novel Oral Anticoagulants

Start date: June 6, 2017
Phase: N/A
Study type: Observational

It is general that there are many factors for individual differences of drugs in clinical application, of which genetic factors accounted for more than 20%. Novel oral anticoagulants-NOACs (include rivaroxaban, apixaban, dabigatran and so on) have advantages of convenient use and no need of monitoring, compared with the traditional vitamin K antagonist. With lack of predicted biomarkers, especially the research data of Chinese, it has the important significance in studying individual differences of NOACs in the anticoagulant efficacy and safety, through the pharmacogenomics research. The aim of this study is to determine the polymorphism of drug metabolizing enzymes, drug transporters and drug target genes in Chinese population. By detecting the gene polymorphism, we intend to study the pharmacokinetic/ pharmacodynamics/ pharmacogenomics (PK-PD-PG) correlation of NOACs and provide scientific basis for accurate medication guide for people to use NOACs.

NCT ID: NCT03161002 Recruiting - Pharmacokinetics Clinical Trials

A Research in Pharmacogenomics and Accurate Medication of New Antiplatelet Drug Ticagrelor

Start date: May 31, 2017
Phase: N/A
Study type: Observational

It is general that there are many factors for individual differences of drugs in clinical application, of which genetic factors accounted for more than 20%. Ticagrelor is a new-type receptor antagonist of P2Y12 and it is not affected by the influence of CYP2C19 polymorphism. With lack of predicted biomarkers, especially the research data of Chinese, it has the important significance in studying individual differences of ticagrelor in the antiplatelet efficacy and safety, through the pharmacogenomics research. The aim of this study is to determine the polymorphism of drug metabolizing enzymes, drug transporters and drug target genes in Chinese population. By detecting the gene polymorphism, we intend to study the pharmacokinetic/ pharmacodynamics/ pharmacogenomics (PK-PD-PG) correlation of ticagrelor and provide scientific basis for accurate medication guide for people to use ticagrelor.